COVID-19

Diagnostics Procurement

The Global Fund is working closely with key partners, international organizations, governments and technical agencies through a World Health Organization-led consortium to rapidly and equitably support access to COVID-19 health products and diagnostics for low- and middle-income countries.

Following the initial allocation of diagnostics tests for COVID-19 (SARS-CoV-2 polymerase chain reaction) from major manufacturers to 140 countries for the May to August 2020 period, WHO has updated the test allocation for September 2020 to February 2021.

The allocation methodology calculates each country’s minimum available volumes by taking each country’s population and adjusting for both vulnerability and epidemiology to support countries with more fragile health systems and/or severe outbreaks, while factoring constraints due to monthly polymerase chain reaction (PCR) testing capacity, if applicable. The vulnerability adjustment is based on the WHO Universal Health Coverage Index and epidemiology is calculated from confirmed cases per population.

PCR tests allocations

WHO has communicated the total volumes available through their country offices and are contained in the list:

  • Diagnostics Consortium Initial Allocation for Cepheid GeneXpert COVID-19 Polymerase Chain Reaction Tests
    download in English

Allocations by the Diagnostics Consortium for other platforms will follow later.

Accessing PCR tests

The WHO allocation model for September 2020 to February 2021 considers any test volumes procured above equitable allocation, either directly with manufacturers or with organizations, to ensure there is equitable distribution of tests to countries.

Today, there is enormous global demand and limited supply availability for diagnosis of COVID-19. Given the challenges in securing these diagnostic products, the Global Fund will follow the WHO allocation model for all its implementing countries and allow the use of grant funds, including COVID-19 Response Mechanism funds, for the purchase of diagnostic products up to the allocation amount. The total number of tests allocated to a country covers all sources of funding to deliver on the intent of WHO allocation to ensure equitable access to low- and middle-income countries. If volumes are accessed through other sources, the Global Fund will consider these as part of the allocation. Available volumes are likely to be lower than demand, and the Global Fund will work closely with manufacturers to quickly allocate any additional volumes that become available.

Principal Recipients with approved funding should submit a request for procurement of these tests through wambo.org or, if not registered to wambo.org, they may contact their Global Fund Country Teams to start the order process.

Governments in Global Fund-eligible and transitioned countries can also procure tests using non-Global Fund sources of funding through wambo.org, or through the other procurement partners of the Diagnostics Consortium. If interested in using wambo.org, contact the Global Fund’s Supply Operations Department or the Country Team for more information.

Where there is a Diagnostics Consortium allocation such as for Cepheid tests, requisitions should be submitted for quantities not greater than the allocation quantity. For further information on the availability of tests for the other platforms, Principal Recipients should contact their Principal Recipient Services focal point in Supply Operations Department or their Country Team.

Read more in our questions and answers document:

  • Ordering COVID-19 Diagnostics (SARS-CoV-2 Polymerase Chain Reaction) through the Global Fund: Frequently Asked Questions
    download in English | Português | Español